The safety and efficacy of tofacitinib in 16 patients with adult-onset atopic dermatitis – a single-center experience
Indian Journal of Skin Allergy · 18.03.2026 · 5 · 74-79
DOI: 10.25259/ijsa_71_2025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Indian Journal of Skin Allergy, online erschienen am 18.03.2026. Verfasst von Ananya Pramanik und 3 weiteren Autor:innen. Die Arbeit nennt 12 Literaturangaben.
Abstract (Originalsprache)
Atopic dermatitis (AD) is an inflammatory condition manifesting with itchy lesions over the body. The distribution and morphology of the lesions differ with age. Adults usually present with lichenification or atypical lesions like head-neck dermatitis, hand eczema, prurigo lesions and seborrheic dermatitis-like lesions. It is a diagnosis of exclusion mainly based on the history and clinical findings. Tofacitinib is a Janus Kinase (JAK) 1 and 3 antagonist. It alters the cytokine expression, thereby suppressing the inflammatory cascade. It has been recently used as an off-label indication in atopic dermatitis with promising outcome. 16 patients of adult-onset AD were started on oral tofacitinib (5 mg twice daily) after relevant baseline investigations were within normal limits. The drug was prescribed for 3 months, and the response was assessed every month based on the improvement in Eczema Area and Severity Index (EASI), SCORing Atopic Dermatitis (SCORAD), Dermatology Life Quality Index (DLQI) and Peak Pruritus Numerical Rating Scale (PP-NRS). All patients showed a considerable reduction in SCORAD, with 10 patients achieving EASI 75 and 3 patients achieving EASI 50. There was significant alleviation of pruritus in all the patients. Tofacitinib was well-tolerated by all patients with minimal side effects. Two patients experienced mild derangement of lipid profile, one developed neutropenia, and two had herpes zoster reactivation. The limitations of the study are a smaller sample size, shorter duration of follow-up and a lack of placebo-control group. This case series suggests tofacitinib to be a remarkable treatment option in AD. Further studies need to be performed to establish its role as a potent steroid-sparing immunosuppressive in AD.
Zitieren
APA
Pramanik, A., Panda, A. K., Panda, M., & Jena, A. K. (2026). The safety and efficacy of tofacitinib in 16 patients with adult-onset atopic dermatitis – a single-center experience. Indian Journal of Skin Allergy, 5, 74-79. https://doi.org/10.25259/ijsa_71_2025
Vancouver
Pramanik A, Panda AK, Panda M, Jena AK. The safety and efficacy of tofacitinib in 16 patients with adult-onset atopic dermatitis – a single-center experience. Indian Journal of Skin Allergy. 2026;5:74-79. doi:10.25259/ijsa_71_2025
BibTeX
@article{Pramanik2026,
author = {Pramanik, Ananya and Panda, Anil Kumar and Panda, Maitreyee and Jena, Ajaya Kumar},
title = {The safety and efficacy of tofacitinib in 16 patients with adult-onset atopic dermatitis – a single-center experience},
journal = {Indian Journal of Skin Allergy},
year = {2026},
volume = {5},
pages = {74--79},
doi = {10.25259/ijsa_71_2025}
}
EUVIMED